EuroBiotech: More Articles of Note

Newspapers

> MorphoSys received FDA breakthrough designation for MOR208 in diffuse large B-cell lymphoma. The FDA awarded the regulatory status to the anti-CD19 antibody on the strength of preliminary data from a phase 2 Revlimid combination trial. Release

> Nicox struck a deal with Re-Vana Therapeutics. The partners will look into combining Nicox’s stand-alone nitric oxide-donors with Re-Vana's biodegradable drug delivery platform. Statement

> UniQure moved to capitalize on the positive response to its pipeline switch up with a stock offering. The gene therapy specialist is offering 5 million shares, positioning it to pull in close to $100 million at its recently-risen stock price. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Ergomed reported top-line data from a phase 2 trial of its coagulant PeproStat. The drug cut time to hemostasis by 1.55 minutes compared to standard of care, a statistically-significant difference that resulted in the trial hitting its primary endpoint. Statement

> Mologen received a $10 million investment from Global Corporate Finance. The money equips Mologen to push ahead with its lefitolimod-focused strategy. Lefitolimod is a clinical-phase TLR9 agonist. Release 

> Transgene reported data from a phase 1/1b trial of its hepatitis B immunotherapy TG1050. Two-fifths of participants experienced drug-related adverse events but none were more severe than grade 2. Most of the adverse events were injection site reactions. Statement

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.